Figure 1. Assessment of clinical and serological response to dupilumab. A: Eosinophilic Esophagitis Activity Index (EEsAI), Asthma Control Test (ACT), and food-induced immediate response of the esophagus (FIRE) episodes were measured up to 24 weeks after initiation of dupilumab. Laboratory tests were performed 8 and 24 weeks after first dose of dupilumab. B: Hematoxylin and eosin staining of esophagus biopsies obtained during gastroscopies before (left) and 10 weeks after (right) treatment with dupilumab. Arrows indicate eosinophils in esophageal mucosa.